p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT). When stratified by PAT and adjusting for other prognostic variables, presence of p53 mutation was associated with a poor outcome (hazard ratio (HR)=3.1, 95% confidence interval (CI), 0.9-11.0) among patients without PAT. Our data confirmed that p53 mutation is an independent pre-treatment factor in stage II and III colorectal cancer after curative resection.
Tang
Reiping
R
Department of Colorectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC.
Wang
Jeng-Yi
JY
Fan
Chung-Wei
CW
Tsao
Kuo-Chien
KC
Chen
Hong-Hua
HH
Wu
Chi-Ming
CM
Chen
Jinn-Shiun
JS
Changchien
Chung Rong
CR
Hsieh
Ling-Ling
LL
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D011905:Genes, ras; D005819:Genetic Markers; D006801:Humans; D008297:Male; D018895:Microsatellite Repeats; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011182:Postoperative Care; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors
D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D005819:Genetic Markers; D005472:Fluorouracil